RetroVirox Inc.

retrovirox.com

RetroVirox is a privately-held biotechnology company founded in 2008 and dedicated to discovering new treatments for patients with infectious diseases. RetroVirox is developing novel drugs to eradicate HIV infection and also to treat infections with highly pathogenic viruses (arenavirus) utilizing company's proprietary technologies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

CIMEIO THERAPEUTICS ANNOUNCES ISSUANCE OF KEY PATENT COVERING CELL THERAPY PLATFORM

Cimeio | November 29, 2022

news image

Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, today announced the U.S. Patent Office has issued a key patent covering the company’s Shielded-Cell & Immunotherapy Pairs platform. U.S. Patent No. 11,499,168 covers a method for in vivo selective depletion of edited primary hematopoietic cells or non-edited primary hematopoietic cells. This method was first discovered and developed in the lab of company founder Lukas Jeker, M.D.,...

Read More

Industrial Impact

NIMBUS THERAPEUTICS ANNOUNCES EXPANSION OF ITS IMMUNOLOGY DRUG DISCOVERY PIPELINE

Nimbus Therapeutics | January 08, 2024

news image

Nimbus Therapeutics, LLC a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, announced the advancement and expansion of its pipeline with the addition of discovery programs targeting innate immunity pathways. These programs, targeting the salt-inducible kinase (SIK) family and cyclic GMP-AMP synthase (cGAS), represent promising opportunities to leverage Nimbus’ industry-leading computational and structure-...

Read More

KYTOPEN PARTNERS WITH CAMBRIDGE CONSULTANTS ON FLOWFECT

Genetic Engineering and Biotechnology News | January 28, 2020

news image

MIT spin-out company Kytopen signed a deal with Cambridge Consultants to co-develop the FlowfectTM system, a scalable process that reportedly yields billions of engineered cells in minutes. The product will streamline the engineering of a wide array of human and human-derived cells for use in next-generation cell therapies, with the goal of expanding access to new medicines, says Paulo Garcia, CEO and co-founder of Kytopen....

Read More

SPPPU AND TUHH SCIENTISTS CREATES CLOSED-LOOP TECHNOLOGY FROM MICROALGAE

QS WOWNEWS | July 18, 2020

news image

Researchers of Peter the Great St. Petersburg Polytechnic University (SPbPU) in collaboration with Hamburg University of Technology (TUHH) completed an international joint project to create a resource and CO2-neutral energy closed-loop technology from microalgae Chlorella sorokiniana and duckweed Lemna minor.According to Professor Kerstin Kuchta, Vice president of TUHH and the project coordinator from the German side, the main objective of the project was development and implementati...

Read More
news image

Cell and Gene Therapy

CIMEIO THERAPEUTICS ANNOUNCES ISSUANCE OF KEY PATENT COVERING CELL THERAPY PLATFORM

Cimeio | November 29, 2022

Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, today announced the U.S. Patent Office has issued a key patent covering the company’s Shielded-Cell & Immunotherapy Pairs platform. U.S. Patent No. 11,499,168 covers a method for in vivo selective depletion of edited primary hematopoietic cells or non-edited primary hematopoietic cells. This method was first discovered and developed in the lab of company founder Lukas Jeker, M.D.,...

Read More
news image

Industrial Impact

NIMBUS THERAPEUTICS ANNOUNCES EXPANSION OF ITS IMMUNOLOGY DRUG DISCOVERY PIPELINE

Nimbus Therapeutics | January 08, 2024

Nimbus Therapeutics, LLC a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, announced the advancement and expansion of its pipeline with the addition of discovery programs targeting innate immunity pathways. These programs, targeting the salt-inducible kinase (SIK) family and cyclic GMP-AMP synthase (cGAS), represent promising opportunities to leverage Nimbus’ industry-leading computational and structure-...

Read More
news image

KYTOPEN PARTNERS WITH CAMBRIDGE CONSULTANTS ON FLOWFECT

Genetic Engineering and Biotechnology News | January 28, 2020

MIT spin-out company Kytopen signed a deal with Cambridge Consultants to co-develop the FlowfectTM system, a scalable process that reportedly yields billions of engineered cells in minutes. The product will streamline the engineering of a wide array of human and human-derived cells for use in next-generation cell therapies, with the goal of expanding access to new medicines, says Paulo Garcia, CEO and co-founder of Kytopen....

Read More
news image

SPPPU AND TUHH SCIENTISTS CREATES CLOSED-LOOP TECHNOLOGY FROM MICROALGAE

QS WOWNEWS | July 18, 2020

Researchers of Peter the Great St. Petersburg Polytechnic University (SPbPU) in collaboration with Hamburg University of Technology (TUHH) completed an international joint project to create a resource and CO2-neutral energy closed-loop technology from microalgae Chlorella sorokiniana and duckweed Lemna minor.According to Professor Kerstin Kuchta, Vice president of TUHH and the project coordinator from the German side, the main objective of the project was development and implementati...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us